Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US.
Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent.
The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and Derivatives Thereof,” is the second of two Bisantrene patents filed in the US, Europe and five other key countries.
“After announcing our first patent allowance last month, we are very pleased to see our second patent also allowed in the world’s most important pharmaceutical market,” said Race CEO, Peter Molloy.
The patent provides commercial protection for new formulations of Bisantrene.
“We have been developing second-generation Bisantrene formulations with potentially improved characteristics over the current Bisantrene product. This patent provides commercial protection for these potential new products,” he said.